Cargando…

Detection of EGFR mutations with mutation-specific antibodies in stage IV non-small-cell lung cancer

BACKGROUND: Immunohistochemistry (IHC) with mutation-specific antibodies may be an ancillary method of detecting EGFR mutations in lung cancer patients. METHODS: EGFR mutation status was analyzed by DNA assays, and compared with IHC results in five non-small-cell lung cancer (NSCLC) cell lines and t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Simonetti, Sara, Molina, Miguel Angel, Queralt, Cristina, de Aguirre, Itziar, Mayo, Clara, Bertran-Alamillo, Jordi, Sanchez, José Javier, Gonzalez-Larriba, Jose Luis, Jimenez, Ulpiano, Isla, Dolores, Moran, Teresa, Viteri, Santiago, Camps, Carlos, Garcia-Campelo, Rosario, Massuti, Bartomeu, Benlloch, Susana, y Cajal, Santiago Ramon, Taron, Miquel, Rosell, Rafael
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2010
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016260/ https://www.ncbi.nlm.nih.gov/pubmed/21167064 http://dx.doi.org/10.1186/1479-5876-8-135

Ejemplares similares

Clinical Validation of a PCR Assay for the Detection of EGFR Mutations in Non–Small-Cell Lung Cancer: Retrospective Testing of Specimens from the EURTAC Trial
por: Benlloch, Susana, et al.
Publicado: (2014)

mRNA expression levels and genetic status of genes involved in the EGFR and NF-κB pathways in metastatic non-small-cell lung cancer patients
por: Santarpia, Mariacarmela, et al.
Publicado: (2011)

c-Met Mutational Analysis in the Sema and Juxtamembrane Domains in Small-Cell-Lung-Cancer
por: de Aguirre, Itziar, et al.
Publicado: (2006)

LungBEAM: A prospective multicenter study to monitor stage IV NSCLC patients with EGFR mutations using BEAMing technology
por: Garrido, Pilar, et al.
Publicado: (2021)

Cost analysis of the management of brain metastases in patients with advanced ALK+ NSCLC: alectinib versus crizotinib
por: Isla, Dolores, et al.
Publicado: (2020)

Anti-epidermal growth factor vaccine antibodies increase the antitumor activity of kinase inhibitors in ALK and RET rearranged lung cancer cells
por: Codony-Servat, Jordi, et al.
Publicado: (2020)

Customized Treatment in Non-Small-Cell Lung Cancer Based on EGFR Mutations and BRCA1 mRNA Expression
por: Rosell, Rafael, et al.
Publicado: (2009)

The predictive value of 53BP1 and BRCA1 mRNA expression in advanced non-small-cell lung cancer patients treated with first-line platinum-based chemotherapy
por: Bonanno, Laura, et al.
Publicado: (2013)

Combinatory effect of BRCA1 and HERC2 expression on outcome in advanced non-small-cell lung cancer
por: Bonanno, Laura, et al.
Publicado: (2016)

Monitoring EGFR-T790M mutation in serum/plasma for prediction of response to third-generation EGFR inhibitors in patients with lung cancer
por: Morán, Teresa, et al.
Publicado: (2018)

Correction: Monitoring EGFR-T790M mutation in serum/plasma for prediction of response to third-generation EGFR inhibitors in patients with lung cancer
por: Morán, Teresa, et al.
Publicado: (2019)

Prognostic model of long-term advanced stage (IIIB-IV) EGFR mutated non-small cell lung cancer (NSCLC) survivors using real-life data
por: Gutiérrez, Lourdes, et al.
Publicado: (2021)

Keynote 407: the combination of pembrolizumab and chemotherapy cracks the shell of squamous cell lung cancer
por: Viteri, Santiago, et al.
Publicado: (2020)

BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer
por: Karachaliou, Niki, et al.
Publicado: (2015)

Author Correction: BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer
por: Karachaliou, Niki, et al.
Publicado: (2023)

Combination of immunotherapy with targeted therapies in advanced non-small cell lung cancer (NSCLC)
por: Moya-Horno, Irene, et al.
Publicado: (2018)

The Prognostic Value of BRCA1 mRNA Expression Levels Following Neoadjuvant Chemotherapy in Breast Cancer
por: Margeli, Mireia, et al.
Publicado: (2010)

Comprehensive cross‐platform comparison of methods for non‐invasive EGFR mutation testing: results of the RING observational trial
por: Romero, Atocha, et al.
Publicado: (2020)

Clinical management and outcome of patients with advanced NSCLC carrying EGFR mutations in Spain
por: Arriola, Edurne, et al.
Publicado: (2018)

Spectrum of CFTR gene mutations in Ecuadorian cystic fibrosis patients: the second report of the p.H609R mutation
por: Ortiz, Sofía C., et al.
Publicado: (2017)

Prospective Exploratory Analysis of Angiogenic Biomarkers in Peripheral Blood in Advanced NSCLC Patients Treated With Bevacizumab Plus Chemotherapy: The ANGIOMET Study
por: Jantus-Lewintre, Eloisa, et al.
Publicado: (2021)

Activation of viral defense signaling in cancer
por: Gonzalez-Cao, Maria, et al.
Publicado: (2018)

Development of a gene panel for next-generation sequencing of clinically relevant mutations in cell-free DNA from cancer patients
por: Malapelle, Umberto, et al.
Publicado: (2017)

AURKB as a target in non-small cell lung cancer with acquired resistance to anti-EGFR therapy
por: Bertran-Alamillo, Jordi, et al.
Publicado: (2019)

Treatment strategy optimization for patients with non-small-cell lung cancer harboring EGFR mutation: a Delphi consensus
por: Isla, D., et al.
Publicado: (2020)

Targeting PD-1/PD-L1 in lung cancer: current perspectives
por: González-Cao, María, et al.
Publicado: (2015)

Expert consensus to optimize the management of older adult patients with advanced EGFR-mutated non-small cell lung cancer
por: Nadal, Ernest, et al.
Publicado: (2023)

Genetic heterogeneity and actionable mutations in HER2-positive primary breast cancers and their brain metastases
por: De Mattos-Arruda, Leticia, et al.
Publicado: (2018)

Liquid Biopsy in Non-Small Cell Lung Cancer
por: Molina-Vila, Miguel A., et al.
Publicado: (2016)

Common Co-activation of AXL and CDCP1 in EGFR-mutation-positive Non-Small Cell Lung Cancer Associated With Poor Prognosis
por: Karachaliou, Niki, et al.
Publicado: (2018)

RB1 gene mutation up-date, a meta-analysis based on 932 reported mutations available in a searchable database
por: Valverde, José R, et al.
Publicado: (2005)

Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer
por: Jacobsen, Kirstine, et al.
Publicado: (2017)

Epidemiology, treatment, and survival in small cell lung cancer in Spain: Data from the Thoracic Tumor Registry
por: Franco, Fernando, et al.
Publicado: (2021)

Prospective detection of mutations in cerebrospinal fluid, pleural effusion, and ascites of advanced cancer patients to guide treatment decisions
por: Villatoro, Sergio, et al.
Publicado: (2019)

Structural and Computational Characterization of Disease-Related Mutations Involved in Protein-Protein Interfaces
por: Navío, Dàmaris, et al.
Publicado: (2019)

Capecitabine and irinotecan with bevacizumab 2-weekly for metastatic colorectal cancer: the phase II AVAXIRI study
por: Garcia-Alfonso, Pilar, et al.
Publicado: (2015)

Assessment of the psychosocial and economic impact according to sex in non-small cell lung cancer patients: an exploratory longitudinal study
por: Viñolas, N. Nuria, et al.
Publicado: (2020)

Effect of Host Species on the Distribution of Mutational Fitness Effects for an RNA Virus
por: Lalić, Jasna, et al.
Publicado: (2011)

Understanding the function and dysfunction of the immune system in lung cancer: the role of immune checkpoints
por: Karachaliou, Niki, et al.
Publicado: (2015)

Insights into EGFR Mutations and Oncogenic KRAS Mutations in Non-Small-Cell Lung Cancer
por: Rosell, Rafael, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_mlllip8o1dda945ifs1g5p40bc